PTC Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
991
IPO date
Jun 20, 2013

PTC Therapeutics is a biotechnology company that focuses on medicines for rare diseases, especially inherited disorders that affect children and small patient groups. It develops drugs meant to treat the root cause of certain genetic conditions, then seeks approval to sell them in the United States and other markets. Its business is narrower than a big drugmaker’s: it concentrates on hard-to-treat diseases where patients have few other options.

The company makes money in two main ways. First, it sells approved specialty medicines directly or through partners. Second, it earns licensing and collaboration payments from larger drug companies that help develop, market, or distribute some of its products. This mix gives PTC both product sales and partner-based revenue.

What makes PTC different is its focus on rare-disease science and the specialized way those drugs reach patients. These medicines often require close work with doctors, insurers, patient groups, and regulators because the target patient populations are small and the diseases are complex. That makes PTC more like a focused rare-disease drug company than a broad pharmaceutical seller.

PTC Therapeutics Inc Investor Relations

Address
500 Warren Corporate Center Drive
Warren, New Jersey
United States of America

Business Segments

Rare disease medicines

PTC develops and sells prescription medicines for people with rare genetic and neurological diseases, including treatments it markets itself and products licensed in certain regions.

Customers

Patients, families, and the specialists and hospitals that prescribe rare disease therapies.

Revenue Model

It earns money from selling its approved medicines and from product royalties tied to licensed drug sales.

Drug development partnerships

PTC works with other pharmaceutical companies and research groups to develop and commercialize certain drug programs and technologies.

Customers

Biopharma partners that want access to PTC’s research, development, or licensing expertise.

Revenue Model

It earns money through collaboration payments, licensing fees, milestone payments, and related research support.

1 / 2

Management

Dr. Stuart W. Peltz Ph.D.

Co-Founder, Senior Consultant & Member of Scientific Advisory Board

Biography unavailable

Dr. Allan Steven Jacobson Ph.D.

Co-Founder, Chairman of Scientific Advisory Board & Independent Director

Biography unavailable

Mr. Pierre Gravier M.S.

Chief Financial Officer

Biography unavailable

Mr. Mark Elliott Boulding J.D.

Executive VP & Chief Legal Officer

Biography unavailable

Mr. Eric Pauwels

Chief Business Officer

Biography unavailable

Dr. Lee Golden M.D., Ph.D.

Executive VP & Chief Medical Officer

Biography unavailable

Dr. Neil Almstead Ph.D.

Chief Technical Operations Officer

Biography unavailable

Ms. Linda Montella Carter

Senior VP & Chief Information Officer

Biography unavailable

Mr. Alex Kane

Investor Relations Officer

Biography unavailable

Ms. Jane Baj

Vice President of Corporate Communications

Biography unavailable

1 / 10